Fortress Biotech, Inc. Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation
Fortress Biotech, Inc. (FBIO) reported Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation of -$82.00 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation · last filed 2018-11-09
- Fortress Biotech, Inc. adjustments to additional paid in capital, income tax deficiency from share-based compensation for the quarter ending 2018-09-30 was $0.00.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation 3 month | Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation 6 month | Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation 9 month |
|---|---|---|---|
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$82.00K 10-Q · filed 2018-11-09 | |
| 2018-06-30 | -$82.00K 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |